Distinguishing new from newsworthy
Peptide research generates a steady stream of novel sequences, and very few of them are meaningfully characterised at the point they first appear. A compound with three in vitro papers and no animal work is a legitimate research subject and an illegitimate basis for confident claims, and the gap between those two positions is where most misinformation in this field originates.
This hub tracks what is genuinely emerging while being explicit about evidence depth. Where a compound is early, that is stated. Where a research direction is promising but unreplicated, that is stated too. The intent is to be useful to researchers deciding where to spend attention rather than to generate excitement.
It also tracks changes in analytical and documentation practice, which move more slowly but affect every lot. Improvements in gradient methodology, mass spectrometry accessibility and reporting convention change what a certificate can be expected to contain.